Navigation Links
Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
Date:9/12/2007

information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

Other Information

In August, Ms. Karen Terrick joined Sunesis as a Director, Regulatory Affairs. In conjunction with her joining, the Compensation Committee of the company's Board of Directors approved an employment commencement grant to Ms. Terrick of a non-qualified stock option to purchase 25,000 shares of Sunesis common stock, effective August 31, 2007. This option award was granted without shareholder approval pursuant to Nasdaq Marketplace Rule 4350 (i)(1)(A)(iv) and with the following material terms: (a) an exercise price equal to the fair market value of the company's common stock on the grant date, (b) a term of ten years, and (c) a vesting schedule providing that the option is exercisable as to one-quarter of the total grant on the first anniversary of Ms. Terrick's hire, and one-forty-eighth of the total grant each month thereafter until the grant is fully vested.

Safe Harbor Statement

This press release contains forward-looking statements, including without limitation statements related to the safety, tolerability and potential efficacy of SNS-595 (alone and in combination with cytarabine) and SNS-314, planned clinical testing and development efforts and the anticipated clinical sites and timing of clinical trials. Words such as "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, Sunesis' drug discovery, development and clinical manufacturing activities could be halted or significantly delayed, Sunesis' clinical trials for SNS-59
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
5. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Edwards Lifesciences Corporation ... of heart valves and hemodynamic monitoring, today announced that ... of Directors. "Bob is an ardent champion for ... true privilege to have him on Edwards, board as we ... , Edwards, chairman and CEO.  "Bob has provided a valuable ...
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... -- Amgen (NASDAQ: AMGN ) today announced financial ... results include: , Total revenues increased 4 ... $5,370 million, with 6 percent product sales growth ... ® (denosumab), Sensipar ® (cinacalcet), Kyprolis ... Unfavorable changes in foreign exchange rates impacted total ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... 8, 2012 Circassia Ltd, a specialty ... ragweed allergy therapy has achieved positive results in a ... with more severe symptoms achieved a significantly greater improvement ... on placebo (p≤0.05).  The results were presented at the ...
... 2012  InfuSystem Holdings, Inc. (NYSE Amex: INFU ... and related services, today announced that it has postponed ... 2011 results originally scheduled for March 8, 2012 in ... complete their audit.  The Company expects to announce financial ...
Cached Medicine Technology:Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results 2Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results 3InfuSystem Postpones Announcement of Fourth Quarter and Fiscal Year 2011 Earnings 2
(Date:7/31/2015)... ... July 31, 2015 , ... The 2015 New ... and family members, medical professionals, and researchers, covering a variety of topics related ... a collaborative effort between the Mesothelioma Applied Research Foundation and Memorial Sloan Kettering ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... 2015”, one of the industry’s premier thought leadership symposiums, hosted by Massachusetts-based ... 6. The event attracts over 250 “C”-level executives, administrators, directors of nursing, ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Mount Sinai Health System ... that evaluate the potential of related, experimental treatments. The collaboration moves into the next ... award Columbia Care one of five state licenses to produce and dispense medical marijuana. ...
(Date:7/31/2015)... ... 31, 2015 , ... Like nearly every other form of surgery, it shouldn't ... more effective and less intrusive and painful. Leading these advances in the United ... Loria currently stands as the only doctor in the United States who is qualified ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Heart Fit Clinic has increased a ... a heart rate of 150 beats versus 100 beats, this is a big deal," ... to give life back to patients with heart disease," he adds. People with angina ...
Breaking Medicine News(10 mins):Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2
... Protection Week March 1-7, 2009 FRAMINGHAM, Mass., March 2 ... the largest increase occurring at corporations and small businesses. ... that 86 percent of data breaches could be prevented, ... Protection Program ( www.identityforce.com/MPP ) in honor of National ...
... Calif., March 2 Based on its recent,analysis ... presents Veran,Medical Technologies, Inc. with the 2009 North ... the Year in recognition of its pioneering,development of ... known as,the IG4, which enables accurate and efficient ...
... System Cart Allows Easier Operation and Improved Workflow ... Traxtal Inc., the pioneer and world leader in ... newly designed system cart for the PercuNav interventional ... Booth # 322 of the Society of Interventional ...
... to new heightsHALIFAX, March 02 /PRNewswire/ - Ocean ... Omega-3 EPA/DHA food and dietary supplement ingredients from ... develop consumer awareness of the health benefits of ... awareness campaign with an interview segment ( http://www.onc.ca/Press/Docs/SEARS-WILLIAM-12.12.08.mp3 ...
... children ages 8-11 years shows contact lens wearers ... and Social Acceptance , JACKSONVILLE, Fla., March ... children beyond simply correcting their nearsightedness -- significantly ... acceptance among friends, and ability to play sports. ...
... software and services company, today announces that it has passed,the ... (TSU) 2009 label. , Misys was ... TSU service came into existence in April 2007 for its ... , The TSU, which has more ...
Cached Medicine News:Health News:New Certification Seal Identifies Merchants Committed to Fighting Identity Theft 2Health News:New Certification Seal Identifies Merchants Committed to Fighting Identity Theft 3Health News:Frost & Sullivan Lauds Veran Medical for its IG4 Plug-n-Play Navigation System 2Health News:Frost & Sullivan Lauds Veran Medical for its IG4 Plug-n-Play Navigation System 3Health News:Frost & Sullivan Lauds Veran Medical for its IG4 Plug-n-Play Navigation System 4Health News:Traxtal to Introduce Next-Generation PercuNav System Cart at SIR Annual Scientific Meeting 2Health News:Dr. William Sears and Ocean Nutrition take flight on American Airlines to Spread Consumer Awareness of the Health Benefits of Omega-3 EPA/DHA 2Health News:Dr. William Sears and Ocean Nutrition take flight on American Airlines to Spread Consumer Awareness of the Health Benefits of Omega-3 EPA/DHA 3Health News:Dr. William Sears and Ocean Nutrition take flight on American Airlines to Spread Consumer Awareness of the Health Benefits of Omega-3 EPA/DHA 4Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 2Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 3Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 4Health News:Misys Wins SWIFTReady TSU 2009 Accreditation for Third Year Running 2Health News:Misys Wins SWIFTReady TSU 2009 Accreditation for Third Year Running 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: